^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

nitroglycerin

Company:
Generic mfg.
Drug class:
Guanylate cyclase stimulant
Related drugs:
4d
Preventing radial artery spasm during cerebral angiography via transradial access by intra-arterial administration of spasmolytic and using The Glidesheath Slender Sheath (ChiCTR2400089250)
P=N/A, N=248, Not yet recruiting, Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Tec
New trial
|
nitroglycerin
2ms
Clinical study on the treatment of stable angina pectoris (Qi deficiency and blood stasis syndrome) with yellow black tea Shengmai decoction (ChiCTR2400086983)
P4, N=86, Not yet recruiting, The First Affiliated Hospital of Henan University of Chinese Medicine; The First Affiliated Hospital of Henan University of Chinese Medicine
New P4 trial
|
nitroglycerin
2ms
The Effect of Nebulizied Nitroglycerin As an Adjuvant Therapy for Persistent Pulmonary Hypertension of Newborns (clinicaltrials.gov)
P=N/A, N=80, Recruiting, Alexandria University | Trial completion date: Aug 2024 --> Jan 2025 | Trial primary completion date: Aug 2024 --> Dec 2024
Trial completion date • Trial primary completion date
|
nitroglycerin
2ms
POINT-NOCAD: PericOronary INflammaTion in Non-Obstructive Coronary Artery Disease (clinicaltrials.gov)
P=N/A, N=32, Active, not recruiting, NYU Langone Health | Recruiting --> Active, not recruiting | N=100 --> 32
Enrollment closed • Enrollment change
|
nitroglycerin
3ms
Role of Sympathetic Activity and Splanchnic Capacitance in Hypertension (clinicaltrials.gov)
P1, N=12, Active, not recruiting, Vanderbilt University | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
Trial completion date • Trial primary completion date
|
nitroglycerin
3ms
Hyaluronidase improves the efficacy of nab-paclitaxel after prolonged angiogenesis inhibition in preclinical models for esophagogastric cancer. (PubMed, Biomed Pharmacother)
These findings suggest that the mechanical barrier of HA is the major reason responsible for the resistance developed during prolonged anti-angiogenesis in EGC. Incorporating PEGPH20 into the existing treatment regimen is promising to improve outcomes for patients with EGC.
Preclinical • Journal
|
CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
|
albumin-bound paclitaxel • DC101 • nitroglycerin • pegvorhyaluronidase alfa (PEGPH20)
4ms
New trial
|
nitroglycerin
5ms
Understanding the Pathophysiology of Migraine Pain (clinicaltrials.gov)
P=N/A, N=10, Recruiting, Montefiore Medical Center | Suspended --> Recruiting | Trial completion date: Dec 2024 --> Jun 2026 | Trial primary completion date: Dec 2024 --> Jun 2026
Enrollment open • Trial completion date • Trial primary completion date
|
nitroglycerin
6ms
Understanding the Pathophysiology of Migraine Pain (clinicaltrials.gov)
P=N/A, N=10, Suspended, Montefiore Medical Center | N=20 --> 10
Enrollment change
|
nitroglycerin
6ms
Screening for ferroptosis genes related to endometrial carcinoma and predicting of targeted drugs based on bioinformatics. (PubMed, Arch Toxicol)
136,572-09-3 BOSS and others were identified as potential targeted drugs for endometrial carcinoma targeting ferroptosis. Our study has shown that ferroptosis-related genes CDKN2A, NRAS and TFRC are diagnostic markers of endometrial carcinoma, and 136,572-09-3 BOSS, methyprylon BOSS, daunorubicin CTD 00005752, nitroglycerin BOSS and dUTP BOSS, IRON BOSS, Imatinib mesylate BOSS, 2-Butanone BOSS, water BOSS, and L-thyroxine BOSS may be potential therapeutic drugs.
Journal
|
NRAS (Neuroblastoma RAS viral oncogene homolog) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
|
imatinib • daunorubicin • nitroglycerin
6ms
NEXT: Effect of Glyceroltrinitrate on Human Energy Expenditure and Brown Adipose Tissue Thermogenesis (clinicaltrials.gov)
P1, N=25, Recruiting, University Hospital, Basel, Switzerland | Trial completion date: Mar 2025 --> Aug 2025 | Trial primary completion date: Dec 2024 --> May 2025
Trial completion date • Trial primary completion date
|
nitroglycerin
7ms
NO AD: Use of Nitric Oxide (NO) Donors for the Prevention of Autonomic Dysreflexia (AD) During Bowel Care Following SCI (clinicaltrials.gov)
P2, N=26, Not yet recruiting, Simon Fraser University | Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025
Trial completion date • Trial primary completion date
|
nitroglycerin
8ms
Enrollment change
|
nitroglycerin
9ms
Topical Nitro or Placebo Pre-Cath (clinicaltrials.gov)
P2, N=256, Not yet recruiting, Thomas Jefferson University
New P2 trial
|
nitroglycerin
9ms
AKI Risk Factors Analysis After Intentional Hypotensive Anesthesia (clinicaltrials.gov)
P=N/A, N=50, Recruiting, Kaohsiung Medical University Chung-Ho Memorial Hospital
New trial • Surgery
|
nitroglycerin
9ms
New trial
|
nitroglycerin
10ms
Enrollment open
|
nitroglycerin
10ms
GTN Therapy on Biomarkers of Immune Escape in Men With Biochemical Recurrence of Prostate Cancer After Primary Therapy (clinicaltrials.gov)
P2, N=43, Completed, Dr. D. Robert Siemens | Unknown status --> Completed | Phase classification: P3 --> P2
Trial completion • Phase classification
|
PD-L1 (Programmed death ligand 1) • TGFB1 (Transforming Growth Factor Beta 1) • ULBP2 (UL16 Binding Protein 2)
|
nitroglycerin
11ms
Understanding the Pathophysiology of Migraine Pain (clinicaltrials.gov)
P=N/A, N=20, Suspended, Montefiore Medical Center | Trial completion date: Dec 2023 --> Dec 2024 | Enrolling by invitation --> Suspended | Trial primary completion date: Dec 2023 --> Dec 2024
Trial completion date • Trial suspension • Trial primary completion date
|
nitroglycerin
1year
High Versus Low Dose Nitroglycerin in Acute Pulmonary Edema (clinicaltrials.gov)
P2/3, N=60, Enrolling by invitation, Alexandria University
New P2/3 trial
|
nitroglycerin
over1year
Fructose supplementation shifts rat brain metabolism in experimental migraine. (PubMed, Brain Res Bull)
We provide novel evidence linking nutrition and metabolism with migraine.
Preclinical • Journal
|
nitroglycerin
over1year
Journal
|
nitroglycerin
over1year
GTN Enhances Antitumor Effects of Doxorubicin in TNBC by Targeting the Immunosuppressive Activity of PMN-MDSC. (PubMed, Cancers (Basel))
We investigated here whether the combination of doxorubicin, a standard chemotherapy in TNBC with glyceryltrinitrate (GTN), a nitric oxide (NO) donor, could overcome chemotherapy resistance and highlight the mechanisms involved in a mouse model of TNBC. (4) We have identified a new combination enhancing the immune-mediated anticancer therapy in a TNBC mouse model through the reprograming of PMN-MDSCs towards a less immunosuppressive phenotype. These findings prompt the testing of GTN combined with chemotherapies as an adjuvant in TNBC patients experiencing treatment failure.
Journal
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
|
doxorubicin hydrochloride • nitroglycerin
over1year
Challenges of Pheochromocytoma Management in a Heart Failure Patient (ENDO 2023)
Subsequent coronary angiogram was aborted due to hypertensive emergency and flash pulmonary edema for which he required IV hydralazine 20 mg, furosemide 80 mg, labetalol 30 mg, verapamil 5 mg, nitroglycerin 800 mg bolus then gtt at 100 mcg/min to achieve hemodynamic stability. He reached the preoperative BP goal after up titration of doxazosin to 12 mg daily and carvedilol to 25 mg twice daily...He was successfully discharged on metoprolol succinate 25 mg, spironolactone 25 mg and losartan 25 mg daily.Clinical Lessons: Preoperative management of pheochromocytoma involves alpha-adrenergic blockade followed by beta-adrenergic blockade to target a BP of <130/80...Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*
Clinical
|
nitroglycerin
over1year
Treatments for brain metastases from EGFR/ALK-negative/unselected NSCLC: A network meta-analysis. (PubMed, Open Med (Wars))
For newly diagnosed BMs, adding chemotherapy, EGFR-TKIs, and other innovative systemic agents (temozolomide, nitroglycerin, endostar, enzastaurin, and veliparib) to radiotherapy did not significantly prolong OS than radiotherapy alone; whereas radiotherapy + nitroglycerin showed significantly better CNS-PFS and ORR...For previously treated BMs, pembrolizumab + chemotherapy, nivolumab + ipilimumab, and cemiplimab significantly prolonged OS than chemotherapy alone...The value of surgery should also be emphasized. The result should be further confirmed by RCTs.
Retrospective data • Journal
|
EGFR (Epidermal growth factor receptor)
|
ALK negative
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • temozolomide • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • Endostar (recombinant human endostatin) • Kinenza (enzastaurin) • nitroglycerin
2years
Gemcitabine-induced digital ischaemia in a patient with metastatic breast cancer. (PubMed, BMJ Case Rep)
She was treated with aspirin, heparin, amlodipine, topical nitroglycerin and analgesics. She had a gradual recovery except for a small necrotic area over the right 4th digit. However, surgical intervention was avoided.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
ER positive + PGR positive • EGFR positive • PGR negative
|
gemcitabine • nitroglycerin • aspirin
over2years
Nitroglycerin-induced downregulation of AKT- and ERK1/2-mediated radiation-sensitive 52 expression to enhance pemetrexed-induced cytotoxicity in human lung cancer cells. (PubMed, Toxicol Res (Camb))
Moreover, NTG synergistically enhanced the cytotoxicity and cell growth inhibition induced by pemetrexed in NSCLC cells; these effects were associated with AKT and ERK1/2 inactivation and, consequently, Rad52 downregulation in H520 and H1975 cells. The results provide a rationale for combining NTG and pemetrexed in lung cancer treatment to improve lung cancer control.
Journal
|
MAP2K1 (Mitogen-activated protein kinase kinase 1) • RAD51 (RAD51 Homolog A) • RAD52 (RAD52 Homolog DNA Repair Protein)
|
pemetrexed • nitroglycerin
over2years
A Unique Case of Paraganglioma Unmasked by Intra-op Hypertension and Abdominal Lymphadenopathy (NKF-SCM 2022)
BP was elevated to 143/113, refractory to bolus anti-hypertensives and a nitroglycerin infusion; he ultimately required a nicardipine infusion for blood pressure control...Labs at the time of diagnosis included Cr elevated to 1.6 mg/dl, troponin peak 1.3 ng/ml, NT-proBNP 291 pg/ml, TSH 3, free plasma metanephrine 108 pg/ml, normetanephrine 7,987 pg/ml, fractionation of norepinephrine >1,200 pg/ml in the serum and >517 mcg/g in the urine, epinephrine 251 pg/ml serum and 21 mcg/g in urine, dopamine 1,144 pg/ml in serum, and chromogranin A 2,058 ng/ml...His BP was controlled on lisinopril and doxazosin with stable BP outpatient of 114/68...Chemotherapy and radiation can be offered as some cases are not ameable to surgery. Performing germline genetic testing should also be considered in such cases.
Clinical
|
SYP (Synaptophysin) • CHGA (Chromogranin A)
|
nitroglycerin
over2years
Nitroglycerin plus whole intracranial radiotherapy for brain metastases in non-small cell lung cancer patients: A randomized, open-label, phase II clinical trial. (PubMed, Int J Radiat Oncol Biol Phys)
The concurrent administration of NTG and radiotherapy improves iORR and ICPFS among NSCLC patients with BM. The benefit is particularly significant in the EGFRm patient subgroup.
P2 data • Journal
|
EGFR (Epidermal growth factor receptor) • HIF1A (Hypoxia inducible factor 1, alpha subunit)
|
EGFR mutation • VEGFA overexpression • VEGFA expression
|
nitroglycerin
3years
Nitric Oxide-Releasing Drug Glyceryl Trinitrate Targets JAK2/STAT3 Signaling, Migration and Invasion of Triple-Negative Breast Cancer Cells. (PubMed, Int J Mol Sci)
We used a subtoxic dose of carboplatin and/or recombinant IL-6 to activate the JAK2/STAT3 signaling pathway and its functional outcomes. We discovered that GTN inhibits the activation of JAK2, the upstream activator of STAT3, and mediates the S-nitrosylation of JAK2. Finally, the effect of GTN (Nitronal) on lung metastasis was investigated to assess its antitumor activity in vivo.
Journal
|
IL6 (Interleukin 6)
|
carboplatin • nitroglycerin
3years
Disulfiram and metformin combination anticancer effect reversible partly by antioxidant nitroglycerin and completely by NF-κB activator mebendazole in hamster fibrosarcoma. (PubMed, Biomed Pharmacother)
Co-treatment with nitroglycerin partly rescued tumor progression, probably by ROS inhibition, while mebendazole completely blocked anticancer activity of the disulfiram and metformin combination, most likely by NF-κB stimulation. Combination of disulfiram with metformin may be used as an effective and safe candidate for novel nontoxic adjuvant and relapse prevention anticancer therapy.
Journal
|
CD34 (CD34 molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PCNA (Proliferating cell nuclear antigen)
|
metformin • nitroglycerin • mebendazole
4years
NVALT12: Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=223, Completed, Dutch Society of Physicians for Pulmonology and Tuberculosis | Recruiting --> Completed | Trial completion date: Aug 2014 --> Aug 2020
Clinical • Trial completion • Trial completion date
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Avastin (bevacizumab) • carboplatin • paclitaxel • nitroglycerin